1
|
Kawachi Y, Ogawa K, Osakabe M, Kawamoto Y, Isobe M, Ida K. Fast-sampling fast-ion D-alpha measurement using multi-anode photomultiplier tube in large helical device. Rev Sci Instrum 2023; 94:103505. [PMID: 37819204 DOI: 10.1063/5.0159175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Accepted: 09/20/2023] [Indexed: 10/13/2023]
Abstract
A fast-sampling fast-ion D-alpha (F-FIDA) measurement has been developed in the large helical device in order to investigate fast ion dynamics associated with helically trapped fast-ion-driven Magnetohydrodynamic (MHD) bursts. F-FIDA consists of a multi-anode photomultiplier tube (PMT) and achieves a sampling rate of 10 kHz. During the deuterium experiment campaign in 2022, F-FIDA measured the spectrum of perpendicular fast ions, using perpendicular lines of sight. We compared F-FIDA with conventional FIDA, using an electron multiplying charge coupled device, and confirmed that the time-averaged images were generally consistent between the two. The statistical properties of the temporal evolution associated with MHD bursts were analyzed using a conditional sampling technique. The results showed that the PMT signal varied in different spatial and wavelength channels. Although the signal-to-noise ratio was poor and there was room for improvement, it could provide useful information for studies on the phase-space dynamics of fast ions.
Collapse
Affiliation(s)
- Y Kawachi
- Department of Electronics, Kyoto Institute of Technology, Matsugasaki, Sakyo Ward, Kyoto 606-8585, Japan
| | - K Ogawa
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, SOKENDAI, Toki, Japan
| | - M Osakabe
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, SOKENDAI, Toki, Japan
| | - Y Kawamoto
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, SOKENDAI, Toki, Japan
| | - M Isobe
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, SOKENDAI, Toki, Japan
| | - K Ida
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
- The Graduate University for Advanced Studies, SOKENDAI, Toki, Japan
| |
Collapse
|
2
|
Koizumi F, Katoh N, Kanehira T, Kawamoto Y, Nakamura T, Kakisaka T, Uchinami Y, Taguchi H, Fujita Y, Takahashi S, Higaki H, Nishioka K, Yasuda K, Kinoshita R, Suzuki R, Miyamoto N, Yokota I, Kobashi K, Aoyama H. A Risk Prediction Model for Severe Radiation Induced Lymphopenia in Patients with Pancreatic Cancer Treated with Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e309. [PMID: 37785118 DOI: 10.1016/j.ijrobp.2023.06.2334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) In pancreatic cancer, radiation induced lymphopenia (RIL) is associated with a poor prognosis. However, normal tissue complication probability (NTCP) models predicting RIL in pancreatic cancer treated with concurrent chemoradiotherapy (CCRT) have yet to be developed. This study aims to develop a least absolute shrinkage and selection operator (LASSO)-based multivariate NTCP model to predict severe RIL in patients with pancreatic cancer during CCRT and to validate the model internally. MATERIALS/METHODS We retrospectively reviewed patients with localized pancreatic cancer who underwent CCRT using three-dimensional conformal radiation therapy from 2013 to 2021. The exclusion criteria were patients with distant metastasis; patients who did not complete RT due to tumor progression; patients who did not have absolute lymphocyte count (ALC) data available before or during RT. An ALC of < 0.5 K/μL during CCRT was defined as severe RIL. A NTCP model of severe RIL was developed by LASSO-based multivariate analysis. We used age, sex, Karnofsky performance status, maximum tumor size, carbohydrate antigen 19-9 level before RT, ALC before RT, volume of planning target volume (PTV), and dosimetric parameters for surrounding organs (including spleen, vertebrae, liver, bilateral kidneys, gastrointestinal tracts) as variables for LASSO. In addition, internal validation was performed by the bootstrap method. The predictive performance of the model was evaluated by the area under the curve (AUC) of the receiver operating characteristic curve and scaled Brier score. RESULTS Of the 131 patients included in the study, the median age was 68 years (range, 42-84), and 55% were male. The median ALC before RT was 1.37 K/µL (0.52-3.50). The median PTV volume was 315.4 ml (86.3-1079.3). The median dose of radiotherapy was 50.4 Gy (16.2-50.4), with 1.8 Gy per fraction. Combination chemotherapy was S-1 in 99 cases (75.6%) and gemcitabine in 32 cases (24.4%). Induction chemotherapy before CCRT was performed in 39 patients (29.8%). Severe RIL was observed in 84 (63.6%) patients. The LASSO showed that low baseline ALC (p = 0.0002), large PTV volume (p < 0.0001), and a large kidney V5 defined as the percentage of bilateral kidneys receiving 5 Gy or more (p = 0.0338) were selected as parameters of the prediction model for severe RIL (AUC = 0.917) and scaled Brier score was 0.511. As a result of internal validation by the bootstrap method, the average AUC was 0.918 (95% confidence interval, 0.849-0.954). CONCLUSION Severe RIL occurred frequently during CCRT for pancreatic cancer, and a NTCP model for severe RIL developed and validated internally in this study showed good predictive performance. External validation is needed before this NTCP model can be used as a benchmark for treatment planning to reduce the risk of severe RIL and for considering future treatment approaches.
Collapse
Affiliation(s)
- F Koizumi
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - N Katoh
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - T Kanehira
- Department of Medical Physics, Hokkaido University Hospital, Sapporo, Japan
| | - Y Kawamoto
- Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - T Nakamura
- Department of Gastroenterological Surgery Ⅱ, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - T Kakisaka
- Department of Gastroenterological Surgery Ⅰ, Hokkaido University Hospital, Sapporo, Japan
| | - Y Uchinami
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - H Taguchi
- Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan
| | - Y Fujita
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - S Takahashi
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - H Higaki
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| | - K Nishioka
- Global Center for Biomedical Science and Engineering, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - K Yasuda
- Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan
| | - R Kinoshita
- Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan
| | - R Suzuki
- Department of Medical Physics, Hokkaido University Hospital, Sapporo, Japan
| | - N Miyamoto
- Department of Medical Physics, Hokkaido University Hospital, Sapporo, Japan
| | - I Yokota
- Department of Biostatistics, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - K Kobashi
- Global Center for Biomedical Science and Engineering, Hokkaido University Faculty of Medicine, Sapporo, Japan
| | - H Aoyama
- Department of Radiation Oncology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
| |
Collapse
|
3
|
Kimura K, Matsuura H, Itoh C, Kawamoto Y, Oishi T, Goto M, Ogawa K, Nishitani T, Isobe M, Osakabe M. Optimization of a fast deuterium diagnostic method based on visible energetic 3He spectroscopy for high electron density plasmas. Rev Sci Instrum 2023; 94:063502. [PMID: 37862490 DOI: 10.1063/5.0110088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 05/22/2023] [Indexed: 10/22/2023]
Abstract
Fast ions play a crucial role in plasma heating, and their behavior in the plasma must be accurately understood. A diagnostics method based on charge exchange emission from the n = 4 - 3 transition (λ0 = 468.6 nm) of energetic 3He produced by the deuteron-deuteron reaction has been proposed as a for fast deuterons with energies in the order of MeV. The proposed method has the following advantages: No beam emission interferes with the spectra, the direction of the measuring line of sight, and the injection angle of the diagnostic beam can be freely determined. In previous studies, due to competing bremsstrahlung, it was expected that the proposed method will not be practical in the case of high electron density operation. This paper makes the proposed method available for measurement even at high electron densities by optimizing the measurement line of sight direction and the diagnostic beam incidence angle. This allows an electron density five times larger than the range of applications shown in previous studies. This result will contribute to measure of DT alpha in ITER.
Collapse
Affiliation(s)
- K Kimura
- Department of Applied Quantum Physics and Nuclear Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan
| | - H Matsuura
- Department of Applied Quantum Physics and Nuclear Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan
| | - C Itoh
- Department of Applied Quantum Physics and Nuclear Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan
| | - Y Kawamoto
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - T Oishi
- Department of Quantum Science and Energy Engineering, Tohoku University, 6-6-01-2 Aobayama, Sendai 980-8579, Japan
| | - M Goto
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- Department of Fusion Science, The Graduate University for Advanced Studies, SOKENDAI, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K Ogawa
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- Department of Fusion Science, The Graduate University for Advanced Studies, SOKENDAI, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - T Nishitani
- Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
| | - M Isobe
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- Department of Fusion Science, The Graduate University for Advanced Studies, SOKENDAI, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M Osakabe
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
- Department of Fusion Science, The Graduate University for Advanced Studies, SOKENDAI, 322-6 Oroshi-cho, Toki 509-5292, Japan
| |
Collapse
|
4
|
Niimi A, Limsirichaikul S, Kano K, Mizutani Y, Takeuchi T, Sawangsri P, Tran DQ, Kawamoto Y, Suzuki M. LASP1, CERS6, and Actin Form a Ternary Complex That Promotes Cancer Cell Migration. Cancers (Basel) 2023; 15:2781. [PMID: 37345118 DOI: 10.3390/cancers15102781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 05/11/2023] [Accepted: 05/11/2023] [Indexed: 06/23/2023] Open
Abstract
CERS6 is associated with metastasis and poor prognosis in non-small cell lung cancer (NSCLC) patients through d18:1/C16:0 ceramide (C16 ceramide)-mediated cell migration, though the detailed mechanism has not been elucidated. In the present study, examinations including co-immunoprecipitation, liquid chromatography, and tandem mass spectrometry analysis were performed to identify a novel binding partner of CERS6. Among the examined candidates, LASP1 was a top-ranked binding partner, with the LIM domain possibly required for direct interaction. In accord with those findings, CERS6 and LASP1 were found to co-localize on lamellipodia in several lung cancer cell lines. Furthermore, silencing of CERS6 and/or LASP1 significantly suppressed cell migration and lamellipodia formation, whereas ectopic addition of C16 ceramide partially rescued those phenotypes. Both LASP1 and CERS6 showed co-immunoprecipitation with actin, with those interactions markedly reduced when the LASP1-CERS6 complex was abolished. Based on these findings, it is proposed that LASP1-CERS6 interaction promotes cancer cell migration.
Collapse
Affiliation(s)
- Atsuko Niimi
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
| | - Siripan Limsirichaikul
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
- Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand
| | - Keiko Kano
- Institute of Transformative Bio-Molecules (WPI-ItbM), Nagoya University, Chikusa, Nagoya 464-8602, Japan
| | - Yasuyoshi Mizutani
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
| | - Toshiyuki Takeuchi
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
| | - Patinya Sawangsri
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
| | - Dat Quoc Tran
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
| | - Yoshiyuki Kawamoto
- Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Kasugai 487-8501, Japan
| | - Motoshi Suzuki
- Department of Molecular Oncology, Fujita Health University, Toyoake 470-1192, Japan
| |
Collapse
|
5
|
Kazahari N, Inoue E, Nakagawa N, Kawamoto Y, Uno T, Inoue-Murayama M. Genetic effects of demographic bottleneck and recovery in Kinkazan Island and mainland populations of Japanese macaques (Macaca fuscata). Primates 2023; 64:239-246. [PMID: 36806706 DOI: 10.1007/s10329-023-01050-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 01/12/2023] [Indexed: 02/23/2023]
Abstract
Populations of Japanese macaques were significantly reduced in most areas from the 1900s to the 1960s and then recovered mainly in the northeastern part of Honshu. A drastic reduction in population size reduces genetic variability through a bottleneck effect. Demographic expansion after the reduction that accumulates new mutations can reduce the bottleneck effects or drive the recovery of genetic variability. We examined the genetic status of a small island population (Kinkazan Island) and a larger mainland population (southern Tohoku) of Japanese macaques that experienced recent demographic bottlenecks and recovery using eight microsatellite loci. The two populations were significantly genetically different from each other. The Kinkazan population exhibited lower genetic variability, remarkable evidence of bottleneck (i.e., significant heterozygosity excess and lower frequency of rare alleles), and a considerably smaller effective population size based on genetic data than based on the current census size. These results indicate that the genetic status has not completely recovered from the demographic bottleneck despite a full recovery in census size on Kinkazan Island. New mutations might rarely have accumulated because of the small carrying capacity of the island. Therefore, the genetic variability of the population would have been restrained by the severe bottleneck size, small carrying capacity, and long-term isolation. On the other hand, the bottleneck effect seems to be limited in the southern Tohoku population considering higher genetic variability, non-significant heterozygosity excess in many mutation conditions, and the highest frequency of rare alleles.
Collapse
Affiliation(s)
- N Kazahari
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo, Kyoto, 606-8203, Japan.
- Field Science Center for Northern Biosphere, Hokkaido University, Sapporo, Japan.
| | - E Inoue
- Faculty of Science, Toho University, Chiba, Japan
| | - N Nakagawa
- Graduate School of Science, Kyoto University, Kyoto, Japan
| | - Y Kawamoto
- Primate Research Institute, Kyoto University, Inuyama, Japan
- Laboratory of Wildlife Medicine, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino, Japan
| | - T Uno
- Tohoku, Monkey and Mammal Management Center, Sendai, Japan
| | - M Inoue-Murayama
- Wildlife Research Center, Kyoto University, 2-24 Tanaka-Sekiden-cho, Sakyo, Kyoto, 606-8203, Japan
| |
Collapse
|
6
|
Yamamura T, Hatanaka K, Harada K, Kawamoto Y, Watanabe R, Nakamura T, Yuki S, Mitsuhashi T, Hatanaka Y, Komatsu Y. 1712P Usefulness of schlafen-11 expression level in cstage II/III esophageal squamous cell carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
7
|
Nakajima T, Wang H, Yuan Y, Ito Y, Naito H, Kawamoto Y, Takeda K, Sakai K, Zhao N, Li H, Qiu X, Xia L, Chen J, Wu Q, Li L, Huang H, Yanagiba Y, Yatsuya H, Kamijima M. Increased serum anti-CYP2E1 IgG autoantibody levels may be involved in the pathogenesis of occupational trichloroethylene hypersensitivity syndrome: a case-control study. Arch Toxicol 2022; 96:2785-2797. [PMID: 35763063 PMCID: PMC9352743 DOI: 10.1007/s00204-022-03326-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 06/01/2022] [Indexed: 01/23/2023]
Abstract
Occupational exposure to trichloroethylene (TCE) causes a systemic skin disorder with hepatitis known as TCE hypersensitivity syndrome (TCE-HS). Human Leukocyte Antigen (HLA)-B*13:01 is its susceptibility factor; however, the immunological pathogenesis of TCE-HS remains unknown. We herein examined the hypothesis that autoantibodies to CYP2E1 are primarily involved in TCE-HS. A case–control study of 80 TCE-HS patients, 186 TCE-tolerant controls (TCE-TC), and 71 TCE-nonexposed controls (TCE-nonEC) was conducted to measure their serum anti-CYP2E1 antibody (IgG) levels. The effects of TCE exposure indices, such as 8-h time-weighted-average (TWA) airborne concentrations, urinary metabolite concentrations, and TCE usage duration; sex; smoking and drinking habits; and alanine aminotransferase (ALT) levels on the antibody levels were also analyzed in the two control groups. There were significant differences in anti-CYP2E1 antibody levels among the three groups: TCE-TC > TCE-HS patients > TCE-nonEC. Antibody levels were not different between HLA-B*13:01 carriers and noncarriers in TCE-HS patients and TCE-TC. The serum CYP2E1 measurement suggested increased immunocomplex levels only in patients with TCE-HS. Multiple regression analysis for the two control groups showed that the antibody levels were significantly higher by the TCE exposure. Women had higher antibody levels than men; however, smoking, drinking, and ALT levels did not affect the anti-CYP2E1 antibody levels. Anti-CYP2E1 antibodies were elevated at concentrations lower than the TWA concentration of 2.5 ppm for TCE exposure. Since HLA-B*13:01 polymorphism was not involved in the autoantibody levels, the possible mechanism underlying the pathogenesis of TCE-HS is that TCE exposure induces anti-CYP2E1 autoantibody production, and HLA-B*13:01 is involved in the development of TCE-HS.
Collapse
Affiliation(s)
- Tamie Nakajima
- Research Institute of Life and Health Sciences, Chubu University, Kasugai, Aichi, 487-8501, Japan.
| | - Hailan Wang
- Laboratory of Key Technology Research, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Yuan Yuan
- Research Institute of Life and Health Sciences, Chubu University, Kasugai, Aichi, 487-8501, Japan
| | - Yuki Ito
- Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
| | - Hisao Naito
- College of Human Life and Environment, Kinjo Gakuin University, Nagoya, Aichi, Japan
| | - Yoshiyuki Kawamoto
- College of Life and Health Sciences, Chubu University, Kasugai, Aichi, Japan
| | - Kozue Takeda
- College of Life and Health Sciences, Chubu University, Kasugai, Aichi, Japan
| | - Kiyoshi Sakai
- Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
| | - Na Zhao
- Laboratory of Key Technology Research, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Hongling Li
- Laboratory of Key Technology Research, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Xinxiang Qiu
- Poison Control Center Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Lihua Xia
- Poison Control Center Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Jiabin Chen
- Poison Control Center Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Qifeng Wu
- Poison Control Center Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Laiyu Li
- Laboratory of Key Technology Research, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, People's Republic of China
| | - Hanlin Huang
- Guangdong Province Hospital for Women and Children Healthcare, Guangdong, People's Republic of China
| | - Yukie Yanagiba
- Division of Industrial Toxicology and Biological Monitoring, National Institute of Occupational Safety and Health, Kawasaki, Kanagawa, Japan
| | - Hiroshi Yatsuya
- Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - Michihiro Kamijima
- Department of Occupational and Environmental Health, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
| |
Collapse
|
8
|
Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Ito K, Saito R, Kobayashi Y, Kato S, Miyagishima T, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y. SO-30 Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
9
|
Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Umemoto K, Izawa N, Nakashima K, Yagisawa M, Kajiura S, Mitsuhashi Y, Ando T, Sunakawa Y, Kikuchi Y, Yamanaka T, Komatsu Y. 499P The safety and efficacy of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
10
|
Permana S, Lukman H, Norahmawati E, Eka Puspita O, Faisal Moh Al Zein D, Kawamoto Y, Tri Endharti A. The combination therapy of targeting both paclitaxel and Dendrophthoe pentandra leaves extract nanoparticles for improvement breast cancer treatment efficacy by reducing TUBB3 and MAP4 expressions. Acta Biochim Pol 2021; 68:679-686. [PMID: 34264566 DOI: 10.18388/abp.2020_5563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Accepted: 04/26/2021] [Indexed: 11/10/2022]
Abstract
The aim of this study is to investigate the combination treatments of paclitaxel and chitosan-Dendrophthoe pentandra leaves extract nanoparticles (NPDP) on MCF-7 breast cancer cells. Chitosan-NPDP nanoparticles were characterized by Fourier-transform infrared (FTIR), scanning electron microscopy (SEM), and assessed by using immunofluorescence microscopy. MCF-7 cells are cultured and divided into six groups: group 1 was a negative control (without paclitaxel or NPDP); group 2 was treated with paclitaxel alone; groups 3-5 were treated with NPDP (2, 4, and 8 mg/mL, respectively) and group 6 was treated only by 8 mg/mL of chitosan-NPDP nanoparticles. The proliferation and cell cycle were analyzed by flow cytometry and the expression of TUBB3 and MAP4 were assessed by immunofluorescence microscopy. The combinations of paclitaxel-NPDP significantly inhibit proliferation of cells (P<0.001) and it is able to induce G2/M cell cycle arrest (P<0.001). The combination of paclitaxel-NPDP significantly decreases the expressions of TUBB3 (P<0.001) and MAP4 (P<0.001) in MCF-7 cells. These results indicate that the combination of NPDP nanoparticles could reduce the expressions of TUBB3 and MAP4. This research may provide possible sources of new therapy for NPDP.
Collapse
Affiliation(s)
- Sofy Permana
- Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia
| | - Hilmia Lukman
- Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Indonesia
| | - Eviana Norahmawati
- Department of Pathology Anatomy, Faculty of Medicine, Universitas Brawijaya, Indonesia
| | - Oktavia Eka Puspita
- Study Program of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Indonesia
| | - Dicky Faisal Moh Al Zein
- Bachelor Program of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia
| | - Yoshiyuki Kawamoto
- Department of Biomedical Sciences, Graduate School of Life and Health Sciences, Chubu University Japan
| | - Agustina Tri Endharti
- Department of Parasitology, Faculty of Medicine, Universitas Brawijaya, Indonesia, Biomedical Central Laboratory, Faculty of Medicine, Universitas Brawijaya, Indonesia
| |
Collapse
|
11
|
Yoshikawa A, Ito K, Yuki S, Kawamoto Y, Saito R, Yamamura T, Yagisawa M, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Sakata Y, Komatsu Y. P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Kato K, Masuishi T, Fushiki K, Nakano S, Kawamoto Y, Narita Y, Tsushima T, Harada K, Kadowaki S, Todaka A, Yuki S, Tajika M, Machida N, Komatsu Y, Yasui H, Muro K, Kawakami T. Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer. ESMO Open 2021; 6:100179. [PMID: 34119801 PMCID: PMC8209093 DOI: 10.1016/j.esmoop.2021.100179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 05/12/2021] [Accepted: 05/16/2021] [Indexed: 11/28/2022] Open
Abstract
Background Nivolumab (NIVO) and irinotecan (IRI) are standard treatments for refractory advanced gastric cancer (AGC); however, it is unclear which drug should be administered first or in which cases. The tumor growth rate (TGR) during preceding treatment is reported to be associated with tumor response in metastatic colorectal cancer patients treated with regorafenib or trifluridine/tipiracil, suggesting that TGR may be useful for drug selection. Therefore, we evaluated the association between TGR during preceding treatment and the tumor response to NIVO or IRI. Patients and methods We retrospectively evaluated consecutive AGC patients treated with NIVO or IRI and divided them into slow-growing (Slow) and rapid-growing (Rapid) groups according to TGR and the presence or absence of new lesions (NL+/NL−, respectively) during preceding treatment (Slow group: NL− with low TGR <0.30%/day; Rapid group: NL+ or high TGR ≥0.30%/day). Results A total of 117 patients (Rapid/Slow groups, 72/45; NIVO/IRI groups, 32/85) were eligible. All baseline characteristics except peritoneal metastases were similar between patients treated with NIVO and IRI in the Rapid and Slow groups. The response rate was significantly higher in patients treated with NIVO compared with IRI [31%/3%; odds ratio (OR), 13.8; P = 0.01; adjusted OR, 52; P = 0.002] in the Slow group, but there was no difference between patients treated with NIVO and IRI (5%/8%; OR, 0.68; P = 0.73; adjusted OR, 0.94; P = 0.96) in the Rapid group. Disease control rate, progression-free survival, and overall survival were consistent with these results. Conclusions Our findings suggest that NIVO treatment is a more favorable option for patients with slow-growing tumors, and NIVO and IRI are similarly recommended for patients with rapid-growing tumors in refractory AGC. TGR and NL emergence during preceding treatment may be helpful for drug selection and warrant further investigation. NIVO and IRI are standard treatments for refractory AGC, although it is unclear which should be administered first. TGR may be useful for drug selection, therefore we evaluated the association between TGR and the tumor response to NIVO or IRI. In the Slow group, the response rate (RR) was significantly higher in patients treated with NIVO compared with IRI. In the Rapid group, there was no significant difference in RR between the NIVO and IRI groups. TGR and NL emergence during preceding treatment may be useful for drug selection.
Collapse
Affiliation(s)
- K Kato
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Masuishi
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
| | - K Fushiki
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - S Nakano
- Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - Y Kawamoto
- Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - Y Narita
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Tsushima
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - K Harada
- Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
| | - S Kadowaki
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - A Todaka
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - S Yuki
- Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
| | - M Tajika
- Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
| | - N Machida
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - Y Komatsu
- Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - H Yasui
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - K Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Kawakami
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| |
Collapse
|
13
|
Shi H, Niimi A, Takeuchi T, Shiogama K, Mizutani Y, Kajino T, Inada K, Hase T, Hatta T, Shibata H, Fukui T, Chen-Yoshikawa TF, Nagano K, Murate T, Kawamoto Y, Tomida S, Takahashi T, Suzuki M. CEBPγ facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation. Cancer Sci 2021; 112:2770-2780. [PMID: 33934437 PMCID: PMC8253294 DOI: 10.1111/cas.14928] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Revised: 04/14/2021] [Accepted: 04/19/2021] [Indexed: 12/25/2022] Open
Abstract
Ceramide synthase 6 (CERS6) promotes lung cancer metastasis by stimulating cancer cell migration. To examine the underlying mechanisms, we performed luciferase analysis of the CERS6 promoter region and identified the Y-box as a cis-acting element. As a parallel analysis of database records for 149 non-small-cell lung cancer (NSCLC) cancer patients, we screened for trans-acting factors with an expression level showing a correlation with CERS6 expression. Among the candidates noted, silencing of either CCAAT enhancer-binding protein γ (CEBPγ) or Y-box binding protein 1 (YBX1) reduced the CERS6 expression level. Following knockdown, CEBPγ and YBX1 were found to be independently associated with reductions in ceramide-dependent lamellipodia formation as well as migration activity, while only CEBPγ may have induced CERS6 expression through specific binding to the Y-box. The mRNA expression levels of CERS6, CEBPγ, and YBX1 were positively correlated with adenocarcinoma invasiveness. YBX1 expression was observed in all 20 examined clinical lung cancer specimens, while 6 of those showed a staining pattern similar to that of CERS6. The present findings suggest promotion of lung cancer migration by possible involvement of the transcription factors CEBPγ and YBX1.
Collapse
Affiliation(s)
- Hanxiao Shi
- Department of Molecular Oncology, School of Medicine, Fujita Health University, Toyoake, Japan.,Division of Molecular Carcinogenesis, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Atsuko Niimi
- Department of Molecular Oncology, School of Medicine, Fujita Health University, Toyoake, Japan
| | - Toshiyuki Takeuchi
- Department of Molecular Oncology, School of Medicine, Fujita Health University, Toyoake, Japan
| | - Kazuya Shiogama
- Department of Morphology and Cell Function, School of Medical Sciences, Fujita Health University, Toyoake, Japan
| | - Yasuyoshi Mizutani
- Department of Molecular Oncology, School of Medicine, Fujita Health University, Toyoake, Japan
| | - Taisuke Kajino
- Division of Molecular Diagnostics, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Kenichi Inada
- Diagnostic Pathology, Bantane Hospital, Fujita Health University, Toyoake, Japan
| | - Tetsunari Hase
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Takahiro Hatta
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Hirofumi Shibata
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Takayuki Fukui
- Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | - Kazuki Nagano
- Department of Pathophysiological Laboratory Science, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Takashi Murate
- Department of Pathophysiological Laboratory Science, Nagoya University Graduate School of Medicine, Nagoya, Japan.,College of Life and Health Sciences, Chubu University, Kasugai, Japan
| | | | - Shuta Tomida
- Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan
| | - Takashi Takahashi
- Division of Molecular Carcinogenesis, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Aichi Cancer Center, Nagoya, Japan
| | - Motoshi Suzuki
- Department of Molecular Oncology, School of Medicine, Fujita Health University, Toyoake, Japan
| |
Collapse
|
14
|
Kimura K, Matsuura H, Kawamoto Y, Oishi T, Goto M, Ogawa K, Nishitani T, Isobe M, Osakabe M. Fast deuteron diagnostics using visible light spectra of 3He produced by deuteron-deuteron reaction in deuterium plasmas. Rev Sci Instrum 2021; 92:053524. [PMID: 34243281 DOI: 10.1063/5.0034683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 04/23/2021] [Indexed: 06/13/2023]
Abstract
The fast deuteron (non-Maxwellian component) diagnostic method, which is based on the higher resolution optical spectroscopic measurement, has been developed as a powerful tool. Owing to a decrease in the D-H charge-exchange cross section, the diagnostic ability of conventional optical diagnostic methods should be improved for ∼MeV energy deuterons. Because the 3He-H charge-exchange cross section is much larger than that of D-H in the ∼MeV energy range, the visible light (VIS) spectrum of 3He produced by the dueteron-dueteron (DD) reaction may be a useful tool. Although the density of 3He is small because it is produced via the DD reaction, improvement of the emissivity of the VIS spectrum of 3He can be expected by using a high-energy beam. We evaluate the VIS spectrum of 3He for the cases when a fast deuteron tail is formed and not formed in the ITER-like beam injected deuterium plasma. Even when the beam energy is in the MeV energy range, a large change appears in the half width at half maximum of the VIS spectrum. The emissivity of the VIS spectrum of 3He and the emissivity of bremsstrahlung are compared, and the measurable VIS spectrum is obtained. It is shown that the VIS spectrum of 3He is a useful tool for the MeV beam deuteron tail diagnostics.
Collapse
Affiliation(s)
- K Kimura
- Department of Applied Quantum Physics and Nuclear Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan
| | - H Matsuura
- Department of Applied Quantum Physics and Nuclear Engineering, Kyushu University, 744 Motooka, Fukuoka 819-0395, Japan
| | - Y Kawamoto
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - T Oishi
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M Goto
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K Ogawa
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - T Nishitani
- Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
| | - M Isobe
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M Osakabe
- National Institute for Fusion Science, National Institutes of Natural Sciences, 322-6 Oroshi-cho, Toki 509-5292, Japan
| |
Collapse
|
15
|
Murakami I, Kato D, Oishi T, Goto M, Kawamoto Y, Suzuki C, Sakaue H, Morita S. Progress of tungsten spectral modeling for ITER edge plasma diagnostics based on tungsten spectroscopy in LHD. Nuclear Materials and Energy 2021. [DOI: 10.1016/j.nme.2021.100923] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Ito K, Harada K, Kawamoto Y, Nakatsumi H, Nakano S, Saito R, Yamamura T, Yuki S, Sakamoto N, Komatsu Y. 1632P Regorafenib is associated with increased skeletal muscle loss in gastrointestinal stromal tumor. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Shindo Y, Nakatsumi H, Yuki S, Kawamoto Y, Muto O, Dazai M, Harada K, Kobayashi Y, Sogabe S, Katagiri M, Kotaka M, Nakamura M, Hatanaka K, Ishiguro A, Tsuji Y, Kobayashi T, Tateyama M, Sasaki Y, Sasaki T, Takagi R, Sakata Y, Komatsu Y. P-112 HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Harada K, Nakano S, Saito R, Ito K, Kawamoto Y, Nakatsumi H, Yuki S, Sakamoto N, Komatsu Y. P-111 Prognostic value of inflammation-based scores for patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
19
|
Ando T, Ito K, Yuki S, Saito R, Nakano S, Nakatsumi H, Kawamoto Y, Dazai M, Miyashita K, Hatanaka K, Harada K, Miyagishima T, Hisai H, Ishiguro A, Ueda A, Kato T, Sasaki T, Shindo Y, Yokota I, Takagi R, Sakata Y, Komatsu Y. P-98 HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Inoue C, Sobue S, Mizutani N, Kawamoto Y, Nishizawa Y, Ichihara M, Takeuchi T, Hayakawa F, Suzuki M, Ito T, Nozawa Y, Murate T. Vaticanol C, a phytoalexin, induces apoptosis of leukemia and cancer cells by modulating expression of multiple sphingolipid metabolic enzymes. Nagoya J Med Sci 2020; 82:261-280. [PMID: 32581406 PMCID: PMC7276413 DOI: 10.18999/nagjms.82.2.261] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Resveratrol (RSV) has recently attracted keen interest because of its pleiotropic effects. It exerts a wide range of health-promoting effects. In addition to health-promoting effects, RSV possesses anti-carcinogenic activity. However, a non-physiological concentration is needed to achieve an anti-cancer effect, and its in vivo bioavailability is low. Therefore, the clinical application of phytochemicals requires alternative candidates that induce the desired effects at a lower concentration and with increased bioavailability. We previously reported a low IC50 of vaticanol C (VTC), an RSV tetramer, among 12 RSV derivatives (Ito T. et al, 2003). However, the precise mechanism involved remains to be determined. Here, we screened an in-house chemical library bearing RSV building blocks ranging from dimers to octamers for cytotoxic effects in several leukemia and cancer cell lines and their anti-cancer drug-resistant sublines. Among the compounds, VTC exhibited the highest cytotoxicity, which was partially inhibited by a caspase 3 inhibitor, Z-VAD-FMK. VTC decreased the expression of sphingosine kinase 1, sphingosine kinase 2 and glucosylceramide synthase by transcriptional or post-transcriptional mechanisms, and increased cellular ceramides/dihydroceramides and decreased sphingosine 1-phosphate (S1P). VTC-induced sphingolipid rheostat modulation (the ratio of ceramide/S1P) is thought to be involved in cellular apoptosis. Indeed, exogenous S1P addition modulated VTC cytotoxicity significantly. A combination of SPHK1, SPHK2, and GCS chemical inhibitors induced sphingolipid rheostat modulation, cell growth suppression, and cytotoxicity similar to that of VTC. These results suggest the involvement of sphingolipid metabolism in VTC-induced cytotoxicity, and indicate VTC is a promising prototype for translational research.
Collapse
Affiliation(s)
- Chisato Inoue
- College of Life and Health Sciences, Chubu University, Kasugai, Japan
| | - Sayaka Sobue
- College of Life and Health Sciences, Chubu University, Kasugai, Japan
| | - Naoki Mizutani
- College of Life and Health Sciences, Chubu University, Kasugai, Japan
| | | | - Yuji Nishizawa
- College of Life and Health Sciences, Chubu University, Kasugai, Japan
| | | | - Toshiyuki Takeuchi
- Department of Molecular Oncology, Fujita Health University, Toyoake, Japan
| | - Fumihiko Hayakawa
- Department of Medical Technology, Nagoya University Graduate School of Health Sciences, Nagoya, Japan
| | - Motoshi Suzuki
- Department of Molecular Oncology, Fujita Health University, Toyoake, Japan
| | - Tetsuro Ito
- Gifu Pharmaceutical University, Gifu, Japan.,Gifu Prefectural Research Institute for Health and Environmental Sciences, Kakamigahara, Japan
| | | | - Takashi Murate
- College of Life and Health Sciences, Chubu University, Kasugai, Japan
| |
Collapse
|
21
|
Ueno Y, Kawamoto Y, Nakane Y, Natsume R, Miura K, Okumura Y, Murate T, Hattori E, Osawa T. Oxidized Perilla and Linseed Oils Induce Neuronal Apoptosis by Caspase-Dependent and -Independent Pathways. Foods 2020; 9:foods9050538. [PMID: 32357550 PMCID: PMC7278870 DOI: 10.3390/foods9050538] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 04/18/2020] [Accepted: 04/22/2020] [Indexed: 11/16/2022] Open
Abstract
Alpha-linolenic acid (ALA), a polyunsaturated fatty acid, is involved in bioregulatory functions. In recent years, the health-promoting effects of vegetable-derived edible oils rich in ALA have attracted attention. ALA has a variety of physiological effects such as anti-arteriosclerotic and antiallergic properties, but is prone to oxidation. Therefore, safety concerns exist with regard to adverse effects on humans induced by its oxides. However, the effects on neuronal cells induced by oxidized ALA-rich oils, such as perilla and linseed oils, have not been fully investigated. This information is very important from the viewpoint of food safety. In this study, we investigated the effects of oxidized perilla and linseed oils, which are rich in ALA, on the toxicity of neuronal SH-SY5Y cells. Perilla and linseed oils were significantly oxidized compared with other edible vegetable oils. These oxidized oils induce neuronal cell death and apoptosis via caspase-dependent and -independent pathways through reactive oxygen species (ROS) generation. Furthermore, they suppressed neurite outgrowth. These results suggest that oxidized perilla and linseed oils have the potential to cause neuronal loss and ROS-mediated apoptosis, and thus may affect the onset and progression of neurodegenerative disorders and other diseases.
Collapse
Affiliation(s)
- Yuki Ueno
- Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
- Correspondence: ; Tel.: +81-561-73-1111
| | - Yoshiyuki Kawamoto
- Department of Biomedical Sciences, Collage of Life and Health Sciences, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - Yamato Nakane
- Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
| | - Risa Natsume
- Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
| | - Kyoko Miura
- Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
| | - Yui Okumura
- Department of Biomedical Sciences, Collage of Life and Health Sciences, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - Takashi Murate
- Department of Biomedical Sciences, Collage of Life and Health Sciences, Chubu University, Kasugai, Aichi 487-8501, Japan
| | - Emi Hattori
- Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
| | - Toshihiko Osawa
- Department of Health and Nutrition, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike Iwasaki-cho, Nisshin, Aichi 470-0195, Japan
| |
Collapse
|
22
|
Hori H, Matsuo J, Teraishi T, Sasayama D, Kawamoto Y, Kinoshita Y, Ota M, Hattori K, Kunugi H. Moderating effect of schizotypy on the relationship between smoking and neurocognition. Eur Psychiatry 2020. [DOI: 10.1016/j.eurpsy.2012.09.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
AbstractPurposeSmoking rates in schizotypic individuals are shown to be elevated, as in patients with schizophrenia, although findings on the association of smoking with different symptomatology of schizotypy have been mixed. Moreover, possible moderating effects of schizotypy on the relationship between smoking and cognition have not been well documented.Subjects and methodsThe Schizotypal Personality Questionnaire (SPQ) and the full version of the Wechsler Memory Scale-Revised (WMS-R) were administered to 501 healthy adults. Subjects were divided into smokers (n = 85) and non-smokers (n = 416) based on the presence/absence of current smoking.ResultsThe analysis of covariance (ANCOVA) on the three factor scores as well as the total score of the SPQ, controlling for age and gender, revealed that cognitive-perceptual factor was significantly associated with an increased rate of smoking (P = 0.048). The ANCOVA on the WMS-R indices, with smoking group as a fixed factor and age, gender and total SPQ score as covariates, revealed that the schizotypy-by-smoking interaction was significant for attention/working memory (P = 0.029).Discussion and conclusionPositive schizotypy may be associated with more smoking. Schizotypy and smoking could interact with each other to negatively affect attention/working memory.
Collapse
|
23
|
Inoue C, Sobue S, Kawamoto Y, Nishizawa Y, Ichihara M, Abe A, Hayakawa F, Suzuki M, Nozawa Y, Murate T. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells. Biochem Biophys Res Commun 2020; 525:1074-1080. [PMID: 32184020 DOI: 10.1016/j.bbrc.2020.02.165] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Accepted: 02/27/2020] [Indexed: 01/04/2023]
Abstract
T315I mutation found in chronic myelogenous leukemia (CML) and Ph + ALL patients is the most serious one among resistance against BCR/ABL kinase inhibitors including imatinib and is only responsive to ponatinib (PNT). However, the novel strategy is required to reduce life-threatening adverse effects of PNT including ischemic cardiovascular disease. We examined the mechanism of PNT-induced cytotoxicity against a T315I(+) Ph + ALL cell line, TccY/Sr. PNT induced apoptosis (increased sub G1 cells, and cleaved caspase3 and PARP), and suppressed protein expression of MCL1, cyclin D2 and c-myc, which were reversed by a proteasome inhibitor, MG132, suggesting enhanced proteasomal degradation by PNT. Among BCL2 family inhibitors, MCL1 inhibitors (maritoclax and AZD5991) robustly induced cell death, showing the MCL1-dependent survival of TccY/Sr cells. Decreased MCL1 and c-myc expression by PNT was also observed in T315I(+) MEGA2/STIR cells. PNT suppressed PI3K activation followed by AKT inhibition and GSK3 dephosphorylation. PI3K/AKT inhibitors mimicked PNT, suggesting that PI3K/AKT signaling is important for survival of TccY/Sr cells. Moreover, GSK3 inhibitor (SB216763) reduced PNT-induced cytotoxicity and degradation of c-myc and MCL1. AZD5991 exhibited the synergistic action with PNT, anti-cancer drugs and venetoclax (BCL2 inhibitor), suggesting the utility of MCL1 inhibitor alone or in combination as a future clinical option for Ph + leukemia patients.
Collapse
Affiliation(s)
- Chisato Inoue
- College of Life and Health Sciences, Chubu University, Kasugai, 487-8501, Japan
| | - Sayaka Sobue
- College of Life and Health Sciences, Chubu University, Kasugai, 487-8501, Japan
| | - Yoshiyuki Kawamoto
- College of Life and Health Sciences, Chubu University, Kasugai, 487-8501, Japan
| | - Yuji Nishizawa
- College of Life and Health Sciences, Chubu University, Kasugai, 487-8501, Japan
| | - Masatoshi Ichihara
- College of Life and Health Sciences, Chubu University, Kasugai, 487-8501, Japan
| | - Akihiro Abe
- Department of Hematology and Oncology, Fujita Health University, Toyoake, 470-1192, Japan
| | - Fumihiko Hayakawa
- Department of Medical Technology, Nagoya University Graduate School of Health Sciences, Nagoya, 461-8673, Japan
| | - Motoshi Suzuki
- Department of Molecular Oncology, Fujita Health University, Toyoake, 470-1192, Japan
| | | | - Takahsi Murate
- College of Life and Health Sciences, Chubu University, Kasugai, 487-8501, Japan.
| |
Collapse
|
24
|
Takeda K, Kawamoto Y, Nagasaki Y, Okuno Y, Goto Y, Iida M, Yajima I, Ohgami N, Kato M. Peptides containing the MXXCW motif inhibit oncogenic RET kinase activity with a novel mechanism of action. Am J Cancer Res 2020; 10:336-349. [PMID: 32064171 PMCID: PMC7017734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 12/26/2019] [Indexed: 06/10/2023] Open
Abstract
REarranged during Transition (RET) is a tyrosine kinase associated with the development of several malignancies. Identification of RET kinase inhibitors promises valuable therapeutic tools for the intervention of RET-driven tumors. Most currently available tyrosine kinase inhibitors target the ATP binding site, but there are several drawbacks of these ATP-competitive drugs. Therefore, there is a need to develop new kinase inhibitors with alternative mechanisms of action. We have previously reported that a conserved cysteine in the MXXCW motif of RET is crucial to the disulfide-bonded dimerization-linked activation of RET kinases. Reagents which bind to this cysteine may inhibit the activity of RET kinases through disulfide-bond mediated dimerization. Here, we examine the potential of MXXCW motif-containing peptides as candidate kinase inhibitors. We demonstrate that MXXCW motif-containing peptides bind to RET in a redox-sensitive manner and block enzymatic activity, causing inhibition of the RET-dependent activity of extracellular signal-regulated kinases and effectively reducing the malignant potential of RET-papillary thyroid carcinoma-1 (PTC)-expressing cells. These motif-containing peptides were also found to be effective against the drug resistant mutant of RET. The inhibition of RET kinase activity by these peptides resulted in suppression of RET-PTC-1-mediated cancer growth. The great potency of these cysteine targeted peptides could indicate promising approaches for novel molecular-targeted therapies for RET-associated cancers.
Collapse
Affiliation(s)
- Kozue Takeda
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
| | - Yoshiyuki Kawamoto
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
| | - Yosuke Nagasaki
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
| | - Yusuke Okuno
- Medical Genomics Center, Nagoya University HospitalNagoya, Japan
| | - Yuko Goto
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
| | - Machiko Iida
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
- Department of Occupational and Environmental Health, Nagoya University Graduate School of MedicineNagoya, Japan
- Division of Perinatology, Institute for Developmental Research, Aichi Human Service CenterKasugai, Aichi, Japan
| | - Ichiro Yajima
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
- Department of Occupational and Environmental Health, Nagoya University Graduate School of MedicineNagoya, Japan
| | - Nobutaka Ohgami
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
- Department of Occupational and Environmental Health, Nagoya University Graduate School of MedicineNagoya, Japan
| | - Masashi Kato
- College of Life and Health Sciences, Chubu UniversityKasugai, Aichi, Japan
- Department of Occupational and Environmental Health, Nagoya University Graduate School of MedicineNagoya, Japan
| |
Collapse
|
25
|
Permana S, Lukman H, Norahmawati E, Eka Puspita O, Faisal Moh Al Zein D, Kawamoto Y, Tri Endharti A. East Asian Genome-wide association study derived loci in relation to type 2 diabetes in the Han Chinese population. Acta Biochim Pol 2019. [PMID: 31145772 DOI: 10.18388/abp.2018_2632] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Meta-analysis of GWAS in East Asian populations had established 10 loci that were associated with type 2 diabetes. Eight of them were with genome-wide significance and two with a border line association. Since these data have not been studied in an independent Han Chinese population, we aimed to investigate the association of these susceptibility loci with type 2 diabetes in an independent Han Chinese population. We executed a case-control study in 2 000 Chinese by the SNPscan method. Firstly, the repetitive sequences of 10 loci were assessed. Next, we investigated the association of 8 SNPs out of 10 with type 2 diabetes and constructed the GRS of those 8 SNPs. Finally, the relationship of the 8 loci and diabetes-related traits was analyzed. Based on the fact, that highly repetitive sequences were detected in 2 SNPs, we investigated the remaining 8 SNPs. With the exception of four SNPs (CMIP rs16955379, PEPD rs3786897, PSMD6 rs831571, ZFAND3 rs9470794), the other SNPs had the same direction of effect (odds ratio [OR]>1.0) as in the original reports, especially GLIS3 rs7041847 and KCNK16 rs1535500 were significantly associated with type 2 diabetes (rs1535500: p=0.005, OR=1.224, 95% CI 1.062-1.409; rs7041847: p=0.035, OR=1.118, 95% CI 1.070-1.388). The GRS constructed from the 8 SNPs was significantly associated with type 2 diabetes in the Chinese population (p=0.004, OR=1.065, 95% CI: 1.021-1.111). Among the participants with 24≤BMI<28 kg/m2 the 8 SNPs were significantly associated with type 2 diabetes (p=0.040, OR=1.079, 95% CI: 1.003-1.160). In quantitative trait analyses, WWOX rs17797882 was associated with decreased HOMA-β and increased level of TG and HDL-Ch, while PEPD rs3786897 and MAEA rs6815464 were associated with decreased fasting plasma glucose, and KCNK16 rs1535500 has shown a significant association with increased T-Ch and PSMD6 rs831571 had a significant association with decreased HDL-Ch. In Conclusion, with high probability the 8 loci identified in the East Asian GWAS meta-analysis are associated with type 2 diabetes in the Han Chinese population.
Collapse
Affiliation(s)
- Sofy Permana
- Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia
| | - Hilmia Lukman
- Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Indonesia
| | - Eviana Norahmawati
- Department of Pathology Anatomy, Faculty of Medicine, Universitas Brawijaya, Indonesia
| | - Oktavia Eka Puspita
- Study Program of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Indonesia
| | - Dicky Faisal Moh Al Zein
- Bachelor Program of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Indonesia
| | - Yoshiyuki Kawamoto
- Department of Biomedical Sciences, Graduate School of Life and Health Sciences, Chubu University Japan
| | - Agustina Tri Endharti
- Department of Parasitology, Faculty of Medicine, Universitas Brawijaya, Indonesia, Biomedical Central Laboratory, Faculty of Medicine, Universitas Brawijaya, Indonesia
| |
Collapse
|
26
|
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 2019; 30:1950-1958. [PMID: 31566666 DOI: 10.1093/annonc/mdz402] [Citation(s) in RCA: 161] [Impact Index Per Article: 32.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration. Gemcitabine plus S-1 (GS) reportedly has equal to, or better, efficacy and an acceptable toxicity profile. We aimed to confirm the non-inferiority of GS to GC for patients with advanced/recurrent BTC in terms of overall survival (OS). PATIENTS AND METHODS We undertook a phase III randomized trial in 33 institutions in Japan. Eligibility criteria included chemotherapy-naïve patients with recurrent or unresectable BTC, an Eastern Cooperative Oncology Group Performance Status of 0 - 1, and adequate organ function. The calculated sample size was 350 with a one-sided α of 5%, a power of 80%, and non-inferiority margin hazard ratio (HR) of 1.155. The primary end point was OS, while the secondary end points included progression-free survival (PFS), response rate (RR), adverse events (AEs), and clinically significant AEs defined as grade ≥2 fatigue, anorexia, nausea, vomiting, oral mucositis, or diarrhea. RESULTS Between May 2013 and March 2016, 354 patients were enrolled. GS was found to be non-inferior to GC [median OS: 13.4 months with GC and 15.1 months with GS, HR, 0.945; 90% confidence interval (CI), 0.78-1.15; P = 0.046 for non-inferiority]. The median PFS was 5.8 months with GC and 6.8 months with GS (HR 0.86; 95% CI 0.70-1.07). The RR was 32.4% with GC and 29.8% with GS. Both treatments were generally well-tolerated. Clinically significant AEs were observed in 35.1% of patients in the GC arm and 29.9% in the GS arm. CONCLUSIONS GS, which does not require hydration, should be considered a new, convenient standard of care option for patients with advanced/recurrent BTC. CLINICAL TRIAL NUMBER This trial has been registered with the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/index.htm), number UMIN000010667.
Collapse
Affiliation(s)
- C Morizane
- Department of Hepatobiliary and Pancreatic Oncology, Tokyo.
| | - T Okusaka
- Department of Hepatobiliary and Pancreatic Oncology, Tokyo
| | - J Mizusawa
- JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo
| | - H Katayama
- JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo
| | - M Ueno
- Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama
| | - M Ikeda
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa
| | - M Ozaka
- Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo
| | - N Okano
- Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo
| | - K Sugimori
- Gastroenterological Center, Yokohama City University Medical Center, Yokohama
| | - A Fukutomi
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka
| | - H Hara
- Department of Gastroenterology, Saitama Cancer Center, Saitama
| | - N Mizuno
- Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya
| | - H Yanagimoto
- Department of Surgery, Kansai Medical University Hospital, Hirakata
| | - K Wada
- Department of Surgery, Teikyo University School of Medicine, Tokyo
| | - K Tobimatsu
- Division of Gastroenterology, Department of Internal Medicine Kobe University Graduate School of Medicine, Kobe
| | - K Yane
- Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo
| | - S Nakamori
- Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka
| | - H Yamaguchi
- Department of Clinical Oncology, Jichi Medical University, Shimotsuke
| | - A Asagi
- Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama
| | - S Yukisawa
- Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya
| | - Y Kojima
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo
| | - K Kawabe
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka
| | - Y Kawamoto
- Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo
| | - R Sugimoto
- Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - T Iwai
- Department of Gastroenterology, Kitasato University Hospital, Sagamihara
| | - K Nakamura
- Division of Gastroenterology, Chiba Cancer Center, Chiba
| | - H Miyakawa
- Department of Bilio-Pancreatology, Sapporo Kousei General Hospital, Sapporo
| | - T Yamashita
- Department of Gastroenterology, Kanazawa University, Kanazawa
| | - A Hosokawa
- Department of Gastroenterology and Hematology, University of Toyama, Faculty of Medicine, Toyama
| | - T Ioka
- Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka
| | - N Kato
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba
| | - K Shioji
- Department of Internal medicine, Niigata Cancer Center Hospital, Niigata
| | - K Shimizu
- Department of Gastroenterology, Tokyo Women's Medical University, Tokyo
| | - T Nakagohri
- Gastroenterological Surgery, Tokai University School of Medicine, Isehara
| | - K Kamata
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka
| | - H Ishii
- Clinical Research Center, Chiba Cancer Center, Chiba, Japan
| | - J Furuse
- Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo
| |
Collapse
|
27
|
Sasaki T, Nakano S, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Ando T, Yoshita H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Komatsu Y. The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
28
|
Sasaki Y, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Miyagishima T, Hatanaka K, Dazai M, Ueda A, Sasaki T, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y. Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Nakamura M, Yuki S, Takahashi N, Shichinohe T, Nakatsumi H, Kawamoto Y, Kusumi T, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Nishimoto N, Komatsu Y. NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz421.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Honda T, Nakano S, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Yoshita H, Ando T, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Tanimoto A, Ishiguro A, Dazai M, Sasaki T, Komatsu Y. A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Kawakami T, Masuishi T, Kawamoto Y, Go H, Shirasu H, Kato K, Kumanishi R, Sawada K, Yamamoto K, Yuki S, Komatsu Y, Yasui H, Muro K, Yamanaka T, Yamazaki K. The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Kawamoto Y, Nakamura Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishina T, Kagawa Y, Oki E, Denda T, Mizukami T, Takahashi N, Okano N, Miki I, Sakamoto Y, Lefterova M, Odegaard J, Taniguchi H, Morizane C, Yoshino T. Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Otaka N, Shibata R, Ohashi K, Uemura Y, Kambara T, Enomoto T, Ogawa H, Ito M, Kawanishi H, Maruyama S, Joki Y, Fujikawa Y, Narita S, Unno K, Kawamoto Y, Murate T, Murohara T, Ouchi N. Myonectin Is an Exercise-Induced Myokine That Protects the Heart From Ischemia-Reperfusion Injury. Circ Res 2019; 123:1326-1338. [PMID: 30566056 DOI: 10.1161/circresaha.118.313777] [Citation(s) in RCA: 109] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
RATIONALE Physical exercise provides benefits for various organ systems, and some of systemic effects of exercise are mediated through modulation of muscle-derived secreted factors, also known as myokines. Myonectin/C1q (complement component 1q)/TNF (tumor necrosis factor)-related protein 15/erythroferrone is a myokine that is upregulated in skeletal muscle and blood by exercise. OBJECTIVE We investigated the role of myonectin in myocardial ischemic injury. METHODS AND RESULTS Ischemia-reperfusion in myonectin-knockout mice led to enhancement of myocardial infarct size, cardiac dysfunction, apoptosis, and proinflammatory gene expression compared with wild-type mice. Conversely, transgenic overexpression of myonectin in skeletal muscle reduced myocardial damage after ischemia-reperfusion. Treadmill exercise increased circulating myonectin levels in wild-type mice, and it reduced infarct size after ischemia-reperfusion in wild-type mice, but not in myonectin-knockout mice. Treatment of cultured cardiomyocytes with myonectin protein attenuated hypoxia/reoxygenation-induced apoptosis via S1P (sphingosine-1-phosphate)-dependent activation of cAMP/Akt cascades. Similarly, myonectin suppressed inflammatory response to lipopolysaccharide in cultured macrophages through the S1P/cAMP/Akt-dependent signaling pathway. Moreover, blockade of S1P-dependent pathway reversed myonectin-mediated reduction of myocardial infarct size in mice after ischemia-reperfusion. CONCLUSIONS These data indicate that myonectin functions as an endurance exercise-induced myokine which ameliorates acute myocardial ischemic injury by suppressing apoptosis and inflammation in the heart, suggesting that myonectin mediates some of the beneficial actions of exercise on cardiovascular health.
Collapse
Affiliation(s)
- Naoya Otaka
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Rei Shibata
- Department of Advanced Cardiovascular Therapeutics (R.S.), Nagoya University Graduate School of Medicine, Japan
| | - Koji Ohashi
- Department of Molecular Medicine and Cardiology (K.O., T.E., N. Ouchi), Nagoya University Graduate School of Medicine, Japan
| | - Yusuke Uemura
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Takahiro Kambara
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Takashi Enomoto
- Department of Molecular Medicine and Cardiology (K.O., T.E., N. Ouchi), Nagoya University Graduate School of Medicine, Japan
| | - Hayato Ogawa
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Masanori Ito
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Hiroshi Kawanishi
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Sonomi Maruyama
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Yusuke Joki
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Yusuke Fujikawa
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Shingo Narita
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Kazumasa Unno
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Yoshiyuki Kawamoto
- Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Kasugai, Japan (Y.K., T. Murate)
| | - Takashi Murate
- Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Kasugai, Japan (Y.K., T. Murate)
| | - Toyoaki Murohara
- From the Department of Cardiology (N. Otaka, Y.U., T.K., H.O., M.I., H.K., S.M., Y.J., Y.F., S.N., K.U., T. Murohara), Nagoya University Graduate School of Medicine, Japan
| | - Noriyuki Ouchi
- Department of Molecular Medicine and Cardiology (K.O., T.E., N. Ouchi), Nagoya University Graduate School of Medicine, Japan
| |
Collapse
|
34
|
Ishiguro A, Yuki S, Takahashi N, Shichinohe T, Nakatsumi H, Kawamoto Y, Kusumi T, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Ito Y, Komatsu Y. North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: final analysis (NORTH/HGCSG1003). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Harada K, Nakano S, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Yoshita H, Ando T, Kobayashi Y, Miyagishima T, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Komatsu Y. A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: analysis of Glasgow prognostic score (GPS). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Nakatsumi H, Komatsu Y, Saito R, Ito K, Nakano S, Kawamoto Y, Yuki S, Sakamoto N. Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y, Kuramochi H, Ohori H, Nakamura M, Takahashi K, Maeda F, Komeno C, Takeuchi M, Fujii M, Yoshino T, Ichikawa W, Tsuji A. RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Ueda A, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Dazai M, Kawahata S, Sasaki T, Sasaki Y, Kato S, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y. Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Ando T, Nakano S, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Yoshita H, Harada K, Kobayashi Y, Miyagishima T, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Sasaki T, Dazai M, Komatsu Y. The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Kawamoto Y, Kondo H, Hasegawa M, Kurimoto C, Ishii Y, Kato C, Botei T, Shinya M, Murate T, Ueno Y, Kawabe M, Goto Y, Yamamoto R, Iida M, Yajima I, Ohgami N, Kato M, Takeda K. Inhibition of mast cell degranulation by melanin. Biochem Pharmacol 2019; 163:178-193. [DOI: 10.1016/j.bcp.2019.02.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 02/12/2019] [Indexed: 10/27/2022]
|
41
|
Dazai M, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Nakano S, Ishiguro A, Tateyama M, Sato A, Kobayashi Y, Nakamura M, Okuda H, Takahashi Y, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y, Komatsu Y. HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Nakamura M, Muranaka T, Yagisawa M, Kawamoto Y, Yuki S, Ishiguro A, Dazai M, Sogabe S, Harada K, Kobayashi Y, Miyagishima T, Okamura N, Tsuji Y, Terae S, Ono K, Komatsu Y. A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Iwanaga I, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Ito Y, Taketomi A, Hirano S, Sakamoto N, Komatsu Y. NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Ishiguro A, Yuki S, Nakano S, Kawamoto Y, Sawada K, Tsuji Y, Honda T, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Yoshikawa A, Kawamoto Y, Yuki S, Nakano S, Sawada K, Muranaka T, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Saiki T, Ishiguro A, Saito R, Ehira N, Iwanaga I, Hatanaka K, Abe N, Sakamoto N, Sakata Y, Komatsu Y. HGCSG1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Suzuki K, Yuki S, Nakano S, Kawamoto Y, Nakatsumi H, Hatanaka K, Ando T, Furukawa K, Ishiguro A, Ohta T, Eto K, Nakajima J, Nakamura M, Sogabe S, Kato K, Tateyama M, Kato S, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Sawada K, Komatsu Y, Muranaka T, Nakano S, Kawamoto Y, Nakatsumi H, Yuki S, Dazai M, Saiki T, Ishiguro A, Tateyama M, Ono K, Ohnishi S, Sakamoto N. The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy (MEC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy444.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
48
|
Izawa N, Morizane C, Takahashi H, Ueno M, Kawamoto Y, Okano N, Shimizu S, Sudo K, Itoh S, Asagi A, Kagawa Y, Kamata K, Kudo T, Nomura S, Kuwata T, Fujii S, Okamoto W, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Tokunaga S, Emi Y, Makiyama A, Kawamoto Y, Komatsu Y, Shimokawa M, Saeki H, Oki E, Baba H, Maehara Y. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Shindo Y, Yuki S, Yagisawa M, Kawamoto Y, Tsuji Y, Hatanaka K, Kobayashi Y, Kajiura S, Ishiguro A, Honda T, Dazai M, Eto K, Nakamura M, Koike M, Ota S, Sato A, Kato K, Ueda A, Fukunaga A, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|